Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: Correlation of results to corresponding tissue block (needle core and excision) samples

Diagnostic Cytopathology

Volumn 41, Issue 3, 2013, Pages 192-198

  Kinsella, Mary D ^a   Birdsong, George G ^b   Siddiqui, Momin T ^a   Cohen, Cynthia ^a   Hanley, Krisztina Z ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

Author keywords

breast cancer; cell block; ER; fine needle aspiration; HER2; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE FIXATION; TISSUE SECTION;

ADENOCARCINOMA; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; FIXATIVES; FORMALDEHYDE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874106553     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21815     Document Type: Article

References (16)

1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
2. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134: e48-e72.
3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: 907-922.
4. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009; 7: S1-S21; quizS22-S23.
5. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4: S1-S26.
6. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F,. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003; 120: 86-92.
7. Werner M, Chott A, Fabiano A, Battifora H,. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24: 1016-1019.
8. Hanley KZ, Siddiqui MT, Lawson D, Cohen C, Nassar A,. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol 2009; 37: 251-257.
9. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009; 133: 775-780.
10. Harvey JM, Clark GM, Osborne CK, Allred DC,. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
11. Williams SL, Birdsong GG, Cohen C, Siddiqui MT,. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: Comparison of cell block and tissue block preparations. Int J Clin Exp Pathol 2009; 2: 476-480.
12. Shabaik A,. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011; 39: 328-332.
13. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV,. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-7735.
14. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG,. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005; 14: 458-465.
15. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008; 21: 1271-1277.
16. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL,. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: A College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med 2010; 134: 728-734.